Cargando…
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa
BACKGROUND: The B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng province, South Africa. Data regarding the seroprevalence of SARS-CoV-2 IgG in Gauteng before the fourth wave of coronavirus disease 2019...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908853/ https://www.ncbi.nlm.nih.gov/pubmed/35196424 http://dx.doi.org/10.1056/NEJMoa2119658 |
_version_ | 1784665964507299840 |
---|---|
author | Madhi, Shabir A. Kwatra, Gaurav Myers, Jonathan E. Jassat, Waasila Dhar, Nisha Mukendi, Christian K. Nana, Amit J. Blumberg, Lucille Welch, Richard Ngorima-Mabhena, Nicoletta Mutevedzi, Portia C. |
author_facet | Madhi, Shabir A. Kwatra, Gaurav Myers, Jonathan E. Jassat, Waasila Dhar, Nisha Mukendi, Christian K. Nana, Amit J. Blumberg, Lucille Welch, Richard Ngorima-Mabhena, Nicoletta Mutevedzi, Portia C. |
author_sort | Madhi, Shabir A. |
collection | PubMed |
description | BACKGROUND: The B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng province, South Africa. Data regarding the seroprevalence of SARS-CoV-2 IgG in Gauteng before the fourth wave of coronavirus disease 2019 (Covid-19), in which the omicron variant was dominant, are needed. METHODS: We conducted a seroepidemiologic survey from October 22 to December 9, 2021, in Gauteng to determine the seroprevalence of SARS-CoV-2 IgG. Households included in a previous seroepidemiologic survey (conducted from November 2020 to January 2021) were contacted; to account for changes in the survey population, there was a 10% increase in the households contacted, with the use of the same sampling framework. Dried-blood-spot samples were tested for IgG against SARS-CoV-2 spike protein and nucleocapsid protein with the use of quantitative assays. We also evaluated Covid-19 epidemiologic trends in Gauteng, including cases, hospitalizations, recorded deaths, and excess deaths from the start of the pandemic through January 12, 2022. RESULTS: Samples were obtained from 7010 participants, of whom 1319 (18.8%) had received a Covid-19 vaccine. The seroprevalence of SARS-CoV-2 IgG ranged from 56.2% (95% confidence interval [CI], 52.6 to 59.7) among children younger than 12 years of age to 79.7% (95% CI, 77.6 to 81.5) among adults older than 50 years of age. Vaccinated participants were more likely to be seropositive for SARS-CoV-2 than unvaccinated participants (93.1% vs. 68.4%). Epidemiologic data showed that the incidence of SARS-CoV-2 infection increased and subsequently declined more rapidly during the fourth wave than it had during the three previous waves. The incidence of infection was decoupled from the incidences of hospitalization, recorded death, and excess death during the fourth wave, as compared with the proportions seen during previous waves. CONCLUSIONS: Widespread underlying SARS-CoV-2 seropositivity was observed in Gauteng before the omicron-dominant wave of Covid-19. Epidemiologic data showed a decoupling of hospitalizations and deaths from infections while omicron was circulating. (Funded by the Bill and Melinda Gates Foundation.) |
format | Online Article Text |
id | pubmed-8908853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Massachusetts Medical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-89088532022-03-21 Population Immunity and Covid-19 Severity with Omicron Variant in South Africa Madhi, Shabir A. Kwatra, Gaurav Myers, Jonathan E. Jassat, Waasila Dhar, Nisha Mukendi, Christian K. Nana, Amit J. Blumberg, Lucille Welch, Richard Ngorima-Mabhena, Nicoletta Mutevedzi, Portia C. N Engl J Med Original Article BACKGROUND: The B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng province, South Africa. Data regarding the seroprevalence of SARS-CoV-2 IgG in Gauteng before the fourth wave of coronavirus disease 2019 (Covid-19), in which the omicron variant was dominant, are needed. METHODS: We conducted a seroepidemiologic survey from October 22 to December 9, 2021, in Gauteng to determine the seroprevalence of SARS-CoV-2 IgG. Households included in a previous seroepidemiologic survey (conducted from November 2020 to January 2021) were contacted; to account for changes in the survey population, there was a 10% increase in the households contacted, with the use of the same sampling framework. Dried-blood-spot samples were tested for IgG against SARS-CoV-2 spike protein and nucleocapsid protein with the use of quantitative assays. We also evaluated Covid-19 epidemiologic trends in Gauteng, including cases, hospitalizations, recorded deaths, and excess deaths from the start of the pandemic through January 12, 2022. RESULTS: Samples were obtained from 7010 participants, of whom 1319 (18.8%) had received a Covid-19 vaccine. The seroprevalence of SARS-CoV-2 IgG ranged from 56.2% (95% confidence interval [CI], 52.6 to 59.7) among children younger than 12 years of age to 79.7% (95% CI, 77.6 to 81.5) among adults older than 50 years of age. Vaccinated participants were more likely to be seropositive for SARS-CoV-2 than unvaccinated participants (93.1% vs. 68.4%). Epidemiologic data showed that the incidence of SARS-CoV-2 infection increased and subsequently declined more rapidly during the fourth wave than it had during the three previous waves. The incidence of infection was decoupled from the incidences of hospitalization, recorded death, and excess death during the fourth wave, as compared with the proportions seen during previous waves. CONCLUSIONS: Widespread underlying SARS-CoV-2 seropositivity was observed in Gauteng before the omicron-dominant wave of Covid-19. Epidemiologic data showed a decoupling of hospitalizations and deaths from infections while omicron was circulating. (Funded by the Bill and Melinda Gates Foundation.) Massachusetts Medical Society 2022-02-23 /pmc/articles/PMC8908853/ /pubmed/35196424 http://dx.doi.org/10.1056/NEJMoa2119658 Text en Copyright © 2022 Massachusetts Medical Society. All rights reserved. http://www.nejmgroup.org/legal/terms-of-use.htm This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections. |
spellingShingle | Original Article Madhi, Shabir A. Kwatra, Gaurav Myers, Jonathan E. Jassat, Waasila Dhar, Nisha Mukendi, Christian K. Nana, Amit J. Blumberg, Lucille Welch, Richard Ngorima-Mabhena, Nicoletta Mutevedzi, Portia C. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa |
title | Population Immunity and Covid-19 Severity with Omicron Variant in South Africa |
title_full | Population Immunity and Covid-19 Severity with Omicron Variant in South Africa |
title_fullStr | Population Immunity and Covid-19 Severity with Omicron Variant in South Africa |
title_full_unstemmed | Population Immunity and Covid-19 Severity with Omicron Variant in South Africa |
title_short | Population Immunity and Covid-19 Severity with Omicron Variant in South Africa |
title_sort | population immunity and covid-19 severity with omicron variant in south africa |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908853/ https://www.ncbi.nlm.nih.gov/pubmed/35196424 http://dx.doi.org/10.1056/NEJMoa2119658 |
work_keys_str_mv | AT madhishabira populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT kwatragaurav populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT myersjonathane populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT jassatwaasila populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT dharnisha populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT mukendichristiank populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT nanaamitj populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT blumberglucille populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT welchrichard populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT ngorimamabhenanicoletta populationimmunityandcovid19severitywithomicronvariantinsouthafrica AT mutevedziportiac populationimmunityandcovid19severitywithomicronvariantinsouthafrica |